社区整合医疗系统实施肝细胞癌监测项目对丙肝肝硬化患者的效果
该回顾性队列研究纳入597例丙肝肝硬化患者,评估基于人群的肝细胞癌监测项目。项目显著提高监测完成率(77.6% vs 5.0%)和覆盖时间比例(80.9% vs 15.8%),监测发现的肝癌更多为单灶、早期且接受治愈性治疗,并改善生存(HR 0.23)。
要点
- 监测项目使丙肝肝硬化患者的HCC监测完成率从5.0%提升至77.6%。
- 监测发现的HCC更常见为单灶、早期且接受治愈性治疗。
- 监测与较低死亡风险相关,校正后HR为0.23。
核心结论
- 实施基于人群的HCC监测项目可显著提高丙肝肝硬化患者的监测利用率和临床结局。
研究设计与样本
- 回顾性队列研究,纳入2013至2020年间在整合医疗系统注册的597例丙肝肝硬化患者,比较入组前后监测模式。
主要发现
- 监测完成率从5.0%提高至77.6%(P<0.001),覆盖时间比例从15.8%提高至80.9%(P<0.001)。
- 监测发现的HCC较首次影像发现者更多为单灶(77.8% vs 44.8%,P<0.001)和早期(85.2% vs 44.8%,P<0.001)。
- 监测发现的HCC最大直径中位数2.3 cm vs 3.2 cm,接受治愈性治疗比例92.5% vs 72.4%(P=0.010)。
关键数值与推荐
- 充分监测定义为入组前和入组后36个月内至少完成5次监测检查。
- 次要结局为36个月内监测覆盖的时间比例。
临床怎么用
- 在丙肝肝硬化患者中推行系统化HCC监测项目可提高早期发现率和治愈性治疗机会。
- 监测项目可能改善生存,可参考本模式设计类似干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Underutilization of hepatocellular cancer (HCC) surveillance has been reported, although data evaluating interventions to improve surveillance are sparse. We assessed the effect of a population-based HCC surveillance program on HCC surveillance utilization and outcomes. METHODS: In this retrospective cohort study, we assessed preinclusion and postinclusion HCC surveillance patterns among 597 patients with hepatitis C virus cirrhosis enrolled in a program at an integrated health system between 2013 and 2020. Adequate surveillance was defined as at least 5 surveillance studies within 36 months pre-enrollment and postenrollment; a secondary outcome was proportion of time covered by surveillance over 36 months. Tumor size, stage, and receipt of curative therapy were compared between HCC detected on the first imaging examination (prevalent HCC) and surveillance-detected HCC (incident HCC). We performed Kaplan-Meier analysis and multivariable competing risk analysis to characterize the association between surveillance and mortality. RESULTS: The surveillance program significantly improved surveillance completion (77.6% vs 5.0%, P < 0.001) and proportion time covered (80.9% vs 15.8%, P < 0.001). Compared with prevalent HCC, surveillance-detected cases were more likely unifocal (77.8% vs 44.8%, P < 0.001), early-stage (85.2% vs 44.8%, P < 0.001), with smaller maximum diameter (median 2.3 vs 3.2 cm), and more likely to undergo curative therapy (92.5% vs 72.4% P = 0.010). Survival was improved compared with prevalent cases hazard ratio (HR) 0.23 (0.11-0.51) after adjusting for age and Model for End Stage Liver Disease score. DISCUSSION: Implementation of a population-based program resulted in significant improvement in HCC surveillance use and clinical outcomes among patients with hepatitis C virus cirrhosis. These findings may inform similar interventions by other healthcare systems.
引用
- Bui H, Kumar NG, Singal AG, et al. Implementation of a Hepatocellular Carcinoma Surveillance Program in a Community-Based Integrated Health System in Patients With Hepatitis C Cirrhosis. Am J Gastroenterol. 2024. PMID: 38334275. doi:10.14309/ajg.0000000000002704
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。